In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 0.31 million shares changing hands with its beta currently measuring 1.51. Company’s recent per share price level of $2.26 trading at $0.04 or 1.80% at ring of the bell on the day assigns it a market valuation of $218.52M. That closing price of ADCT’s stock is at a discount of -167.26% from its 52-week high price of $6.04 and is indicating a premium of 69.47% from its 52-week low price of $0.69. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 382.66K if we extend that period to 3-months.
For Adc Therapeutics SA (ADCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Adc Therapeutics SA (NYSE:ADCT) trade information
Upright in the green during last session for gaining 1.80%, in the last five days ADCT remained trading in the green while hitting it’s week-highest on Tuesday, 11/26/24 when the stock touched $2.26 price level, adding 5.04% to its value on the day. Adc Therapeutics SA’s shares saw a change of 36.14% in year-to-date performance and have moved 14.14% in past 5-day. Adc Therapeutics SA (NYSE:ADCT) showed a performance of -24.92% in past 30-days. Number of shares sold short was 3.16 million shares which calculate 8.61 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 71.75% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -209.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -209.73% for stock’s current value.
Adc Therapeutics SA (ADCT) estimates and forecasts
Statistics highlight that Adc Therapeutics SA is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -34.30% of value to its shares in past 6 months, showing an annual growth rate of 41.16% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 4.38% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 18.85M for the same. And 2 analysts are in estimates of company making revenue of 20.27M in the next quarter. Company posted 16.79M and 18.05M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 84.52% during past 5 years.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Insiders are in possession of 21.03% of company’s total shares while institution are holding 61.50 percent of that, with stock having share float percentage of 77.88%. Investors also watch the number of corporate investors in a company very closely, which is 61.50% institutions for Adc Therapeutics SA that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at ADCT for having 15.27 million shares of worth $48.25 million. And as of 2024-06-30, it was holding 18.4964 of the company’s outstanding shares.
The second largest institutional holder is PROSIGHT MANAGEMENT, LP, which was holding about 9.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.5926 of outstanding shares, having a total worth of $30.24 million.
